A chemical restraint is a medication given to control a person’s behavior or restrict their movement, rather than to treat a diagnosed medical or psychiatric condition. That distinction is critical: the same drug can be a legitimate treatment in one context and a chemical restraint in another, depending on why it’s being given. Federal regulations, medical ethics guidelines, and patient rights laws all treat chemical restraints differently from standard medication, with stricter rules about when and how they can be used.
How Chemical Restraints Differ From Treatment
The federal definition, codified by the Centers for Medicare and Medicaid Services, draws a clear line. A chemical restraint is “a medication used to control behavior or to restrict the participant’s freedom of movement” that “is not a standard treatment for the participant’s medical or psychiatric condition.” In practice, this means an antipsychotic given to someone with schizophrenia as part of their treatment plan is not a chemical restraint. The same antipsychotic given to a nursing home resident without a psychiatric diagnosis, simply because they’re wandering or being difficult for staff, is one.
This line is harder to draw than it sounds. Psychotropic medications like antipsychotics have approved clinical uses, and prevalence studies consistently struggle to determine what proportion of prescriptions reflect an intent to restrain versus genuine treatment. There is no published international consensus definition of chemical restraint, which makes tracking and regulating it even more difficult.
What Medications Are Involved
Three drug classes are most commonly used as chemical restraints: benzodiazepines (sedatives that reduce anxiety and cause drowsiness), older antipsychotic medications sometimes called neuroleptics, and newer atypical antipsychotics. All of these work by altering brain chemistry to produce sedation, reduce agitation, or suppress psychotic symptoms. More recently, ketamine, a powerful anesthetic, has become part of the conversation, particularly in emergency and pre-hospital settings.
The choice of drug depends on the setting. Emergency departments tend to use fast-acting sedatives that can be injected. Long-term care facilities more often rely on antipsychotics given daily in pill form, sometimes for weeks or months.
Where Chemical Restraints Are Used
Chemical restraints come up in several distinct settings, each with its own dynamics. In emergency departments, they may be used on patients who are severely agitated and pose an immediate physical danger to themselves or staff. In psychiatric facilities, they can be part of managing acute crises. In nursing homes and long-term care, they have historically been used to manage residents with dementia who exhibit agitation, wandering, or aggression.
The justification in every case centers on preventing harm, either to the individual or to others. But the bar for what counts as sufficient danger varies enormously between a chaotic emergency room and a quiet nursing home hallway, which is why oversight standards differ across these settings.
Serious Risks for Older Adults
The use of antipsychotics as chemical restraints in elderly people with dementia carries well-documented dangers. The FDA issued a public health advisory after reviewing 17 controlled studies that showed elderly dementia patients treated with atypical antipsychotics were 1.6 to 1.7 times more likely to die than those given a placebo. Deaths resulted from heart failure, sudden cardiac events, and infections like pneumonia.
The FDA required manufacturers to add a black box warning, the most serious type of safety label, stating that these drugs are “not approved for the treatment of behavioural symptoms in elderly patients with dementia.” The affected medications include some of the most widely prescribed antipsychotics: aripiprazole, olanzapine, quetiapine, risperidone, clozapine, and ziprasidone. Despite these warnings, antipsychotic use in nursing homes remains a persistent concern, and advocacy groups have pushed for years to reduce what they call the “chemical restraint” of dementia patients.
The Ketamine Controversy
One of the most heated recent debates involves paramedics using ketamine to sedate agitated people in the field, often at the request of law enforcement. Ketamine is not FDA-approved for managing agitation, and its labeling specifies it should only be used by physicians experienced in administering general anesthetics and maintaining airways. Despite this, emergency medical services in some regions adopted protocols allowing paramedics to inject ketamine into people detained by police.
The central justification was a condition called “excited delirium,” described as extreme agitation with violent behavior and supposedly superhuman strength. That diagnosis has since been widely rejected. The American Medical Association, the American Psychiatric Association, and other major organizations have questioned or rejected it, and it is now broadly viewed as a pseudodiagnosis used to explain deaths that occurred during police encounters. In 2022, the Minneapolis Police Department stopped using the term entirely. Two years later, Minnesota’s governor signed a law prohibiting police training on the concept.
The human cost of these practices became starkly visible in 2019, when paramedics in Aurora, Colorado, forcibly administered a large dose of ketamine to Elijah McClain, a 23-year-old Black man, after police detained him and paramedics diagnosed him with excited delirium. McClain went into cardiac arrest and was taken off life support four days later. In 2023, the paramedics who sedated him were convicted of criminally negligent homicide. One received a five-year prison sentence for administering a drug without consent or legitimate medical purpose.
Legal and Ethical Requirements
The American Medical Association’s ethics guidelines establish several key rules. Outside of emergencies, patients should only be restrained on a physician’s explicit order. Informed consent is required: the patient (or their surrogate, if the patient lacks decision-making capacity) must be told why restraint is recommended, what type will be used, and how long it’s intended to last.
When a patient poses a significant danger to themselves or others, involuntary restraint may be appropriate. Even then, two principles apply. The least restrictive option reasonable must be chosen first. And the restraint must be removed as soon as it’s no longer needed. These are not just ethical preferences; they carry legal weight. Using chemical restraints without proper justification, consent, or physician oversight can result in civil liability and, as the McClain case demonstrated, criminal prosecution.
Alternatives That Reduce Restraint Use
A growing body of evidence supports approaches that reduce or eliminate the need for chemical restraints. Verbal de-escalation is the first-line strategy in most emergency settings: one-on-one dialogue, respecting personal space, speaking concisely, identifying the person’s needs and feelings, and setting clear limits. When de-escalation alone isn’t enough, a brief time-out or pastoral care can help before escalating to medication.
In long-term care settings for older adults, the approach is different but equally effective. Regularizing daily routines, minimizing schedule disruptions, ensuring consistent mealtimes, making daily tasks easier, and addressing untreated pain all reduce the agitation that leads to restraint use. Staff training matters enormously. Programs that teach caregivers to recognize behavioral triggers, modify the environment to reduce ambient stress, and shift their interaction style with residents have shown measurable reductions in restraint use.
Behavioral interventions in institutional settings include gradually reducing restraint use over time (restraint fading), changing the criteria for when restraints are applied and removed, and conducting structured behavioral observations so staff can identify patterns in a patient’s agitation rather than simply reacting to each episode.